reMYND, a trusted research partner

Our Contract Research Organization (CRO) helps our clients assess in-vivo characteristics, pharmacokinetics, pharmacodynamics and the effects of their experimental treatments against Alzheimer's disease in our proprietary Alzheimer mouse models.

We serve the majority of the Top 10 pharmaco’s worldwide with clients in the US, Europe and Japan. We have provided pivotal in-vivo proof-of-concept data for several candidate drugs currently in clinical development, and work actively together with Dr. Sugimoto, the inventor of Aricept. We have helped our clients to be the first to demonstrate the synergistic effect of a BACE inhibitor and an aBeta antibody, the effect of Tau antibody on aBeta, the effect of donepezil on brain Abeta,… 

The continuous availability of aged mice allows for a short response time and rapid study start. By contributing our extensive expertise and experience we are helping our clients to set up an optimal study design. The CRO offers a broad testing window for our portfolio of behavioral readouts in combination with all routes of administration, as well as immunohistochemical and biochemical read-outs, both in brain and cerebrospinal fluid (CSF).

Aβ pathology

Tau pathology

Astrocytosis and microgliosis

Neuronal loss

Cognitive impairment

Motoric impairment

Other behavior

LTP deficit

Impaired survival

CSF Biomarker

APP[V717I]

APP[V717I]xPS1[A246E]

Tau[P301L]

Tau[P301S]

APP[V717I]xTau[P301S]

Seed and spread Tauopathy model

has been investigated and shown to be present

APP[V717I]

The APP[V717I] (APP-London, APP-Ld) mouse model recapitulates important pathological and clinical hallmarks of Alzheimer’s disease and has proven to be a valuable paradigm for evaluating Ab directed therapies. The APP-london based model is a preferred model for testing anti-beta-secretase and anti-gamma-secretase associated approaches since it has a wildtype BACE-cleavage site which does not interfere with the mechanism of action of the compound. This model has been extensively used to assess experimental treatments that are currently in clinical testing.

Read more
APP[V717I]xPS1[A246E]

The APP[V717I]xPS1[A246E] mouse model develops similar characteristics as the APP[V717I], but at an accelerated pace.

Read more
Tau[P301L]

reMYND’s Tau[P301L] model exhibits a progressive hyperphosphorylation leading to a profound neurofibrillary tangle pathology and serves as an excellent tauopathy model for studying  FTD and Alzheimer’s disease. Additionally, this model has been extensively used to assess experimental treatments that are currently in clinical testing.

Read more
Tau[P301S]

reMYND’s Tau[P301S] model exhibits a progressive hyperphosphorylation leading to a fast progressing and profound neurofibrillary tangle pathology and serves as an excellent tauopathy model for FTD and Alzheimer’s disease.

Read more
APP[V717I]xTau[P301S]

Three important characteristics of Alzheimer’s disease are recapitulated in this model: intracellular neurofibrillary tangles (NFTs), extracellular amyloid plaques and cognitive impairment.

Read more
APP[V717I]xTau[P301L]

Three important characteristics of Alzheimer’s disease are recapitulated in this model: intracellular neurofibrillary tangles (NFTs), extracellular amyloid plaques and cognitive impairment.

Read more